Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

NCT04586543 is registered in ClinicalTrials.gov with László Mangel as lead sponsor.

NCT NCT04586543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04586543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
Lead sponsor
László Mangel
Phase
Phase 2
Overall status
Unknown status
Start date
May 18, 2020
Completion date
February 1, 2025
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, metastatic castration-resistant prostate cancer